miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5

Yuan, Chao; Su, Zhonggen; Liao, Shengjie; Li, Duanzhuo; Zhou, Zhiwen; Wang, Yawen; Quan, Mingchun; Zeng, Lingling; Lv, Cai; Shen, Chenyi; Gong, Weida; Wu, Jianfeng; Chen, Xiaogang; Hu, Wenbing; Lv, Xu Liang; Si, Wenxia; Yu, Xuezhong

doi:10.1186/s12935-021-02092-7

Cited by 7 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total RNA was extracted from the cells using the TRIzol kit (Takara, Dalian, China) as described previously (18). 1 mg RNA was used to transcribe cDNA using the HiScript II Q RT SuperMix (R223-01, Vazyme).…”

Section: Qrt-pcr Assaymentioning

confidence: 99%

See 1 more Smart Citation

Triptolide inhibits the progression of Glioblastoma U251 cells via targeting PROX1

Yuan

Liao²,

Liao³

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

BackgroundGlioblastoma multiforme (GBM) is the most lethal brain cancer in adults, characterized by rapid growth, extensive invasiveness, and poor prognosis, and there is still a lack of effective treatments. Here, we aimed to explore the role of triptolide (TPL), purified from Tripterygium wilfordii Hook F, on glioblastoma cell growth, apoptosis, proliferation, migration and invasion, as well as potential underlying mechanisms.MethodsThe publicly available clinical data of Brain Lower Grade Glioma (LGG) from The Cancer Genome Atlas (TCGA) had been screened to observe PROX1 expression. The Kaplan-Meier analysis was used to analyze the relationship between PROX1 expression and GBM prognosis. CCK8, cell cycle, EDU, apoptosis, wound healing, and transwell assays were performed to detect the effects of TPL on glioblastoma U251 cell viability, cell cycle, proliferation, apoptosis, migration and invasion, respectively. Further, a soft agar colony assay was used to calculate the growth of glioblastoma cells. The qRT-PCR and western blot were conducted to quantify PROX1 mRNA and protein levels. The transcriptional regulation of TPL was detected by Dual luciferase reporter assay.ResultsWe found that TPL inhibited glioblastoma cell viability, proliferation, cell cycle, migration and invasion, but enhanced apoptosis in a dose-dependent manner. The expression of cell cycle inhibitor, P21, and pro-apoptosis factor, Bax was increased, while invasion-related factors MMP2 and MMP9 were silenced after TPL treatments. Mechanistically, TPL showed transcriptional inhibition of PROX1 appearance. Moreover, ectopic expression of PROX1 partially rescued the effects of TPL on glioblastoma cell viability, proliferation, apoptosis, migration and invasion, and on the expression of cell function-related genes.ConclusionThis study verified that TPL inhibited the progression of glioblastoma cells by transcriptionally depressing the expression of PROX1.

show abstract

Section: Qrt-pcr Assaymentioning

confidence: 99%

“…Cell counting kit-8 (CCK-8) assay (Beyotime) was performed to evaluate the U251cell viability as before (18). Briefly, 1x10 5 U251cells were seeded in a 96-well plate (NEST, China) for 24 h, and then treated with different concentrations of TPL for another 24h.…”

Section: Cck8 Assaymentioning

confidence: 99%

Triptolide inhibits the progression of Glioblastoma U251 cells via targeting PROX1

Yuan

Liao²,

Liao³

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[16] miRNA is another form of ncRNAs, which plays a major role in many malignant behaviors of human tumors. [17,18] As a tumor suppressor, miR-198 has been found to be less expressed in some tumors, such as renal cell carcinoma (RCC), [19] CRC, [20] osteosarcoma (OS), [21] and GC. [22] Of course, miR-198 is downregulated in OC tissues.…”

Section: Introductionmentioning

confidence: 99%

Knockdown of circMFN2 inhibits cell progression and glycolysis by miR‐198/CUL4B pathway in ovarian cancer

Song

Chai

Liu

et al. 2023

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Circular RNA (circRNA) regulates malignant tumors, including ovarian cancer (OC). The present research study aimed to reveal the biological mechanism of circRNA mitofusin 2 (circMFN2) in OC. Cell biological behaviors were investigated using clonogenicity assay, EdU assay, transwell assay, and flow cytometry analysis. Quantitative reverse transcription polymerase chain reaction (qRT‐PCR) and western blot analysis were implemented to detect the levels of circMFN2, miR‐198, Cullin 4B (CUL4B), and apoptosis‐related proteins. Glycolysis was assessed by glucose assay kit, lactate assay kit, and ATP level detection kit. The relationships among miR‐198, circMFN2, and CUL4B were verified by dual‐luciferase reporter assay and RNA immunoprecipitation assay. The xenograft mice model was used to analyze tumor growth in vivo. The expression of circMFN2 and CUL4B was increased, while miR‐330‐5p was decreased in OC tissues or cells. The absence of CircMFN2 hindered cell proliferation, migration, invasion, and glycolysis and promoted apoptosis in OC cells. We found that circMFN2 promoted CUL4B expression via sponging miR‐198. MiR‐198 depletion reversed circMFN2 knockdown‐induced effects in OC cells. Furthermore, CUL4B overexpression overturned the inhibitory effect of miR‐198 in OC cells. And the absence of circMFN2 inhibited tumor growth in vivo. CircMFN2 repressed OC progression by regulating the miR‐198/CUL4B axis.

show abstract

“…These data indicate that miR-198 has therapeutic potential for PC. miR-198 has been shown to have a potent tumor-suppressor function in other types of cancers including renal cell carcinoma, ovarian cancer, lung cancer, and prostate cancer [ 59 , 60 , 61 , 62 ]. Furthermore, many studies have demonstrated that miR-520h could significantly inhibit tumor progression or prevent chemotherapy drug resistance in different types of cancers such as PC, multiple myeloma, and gastric cancer [ 63 , 64 , 65 ].…”

Section: Introductionmentioning

confidence: 99%

Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids

et al. 2021

View full text Add to dashboard Cite

We previously reported a new polymer, lactic-co-glycolic acid-polyethylenimine (LGA-PEI), as an improved nanoparticle (NP) delivery for therapeutic nucleic acids (TNAs). Here, we further developed two antibody (Ab)-conjugated LGA-PEI NP technologies for active-targeting delivery of TNAs. LGA-PEI was covalently conjugated with a single-chain variable fragment antibody (scFv) against mesothelin (MSLN), a biomarker for pancreatic cancer (PC), or a special Ab fragment crystallizable region-binding peptide (FcBP), which binds to any full Ab (IgG). TNAs used in the current study included tumor suppressor microRNA mimics (miR-198 and miR-520h) and non-coding RNA X-inactive specific transcript (XIST) fragments; green fluorescence protein gene (GFP plasmid DNA) was also used as an example of plasmid DNA. MSLN scFv-LGA-PEI NPs with TNAs significantly improved their binding and internalization in PC cells with high expression of MSLN in vitro and in vivo. Anti-epidermal growth factor receptor (EGFR) monoclonal Ab (Cetuximab) binding to FcBP-LGA-PEI showed active-targeting delivery of TNAs to EGFR-expressing PC cells.

show abstract

miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5

Cited by 7 publications

References 26 publications

Triptolide inhibits the progression of Glioblastoma U251 cells via targeting PROX1

Triptolide inhibits the progression of Glioblastoma U251 cells via targeting PROX1

Knockdown of circMFN2 inhibits cell progression and glycolysis by miR‐198/CUL4B pathway in ovarian cancer

Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids

Contact Info

Product

Resources

About